HER-2 is a one of the most widely used tumour markers in breast cancer, and HER-2 gene amplification results in poor prognosis, resistance to hormonal therapies and generally to more aggressive breast cancer phenotype (Slamon et al, 1987; Ross et al, 2009). This evidence concerns the gene ERBB2 and breast carcinoma.